YES1

YES proto-oncogene 1, Src family tyrosine kinase

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Mutation + YES1 AmplificationEGFR YES11
Afatinib	Lung Adenocarcinoma	Predictive	D	Supports Resistance

Cohorts

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved14 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma TCGA-DLBC	Diffuse Large B-Cell LymphomaCURATED_BROADER

Literature

Data not yet available

No publication linked to this gene yet.

ERBB2 Amplification + YES1 AmplificationERBB2 YES12
Neratinib	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID12095 Neratinib-resistant cell lines were established by stepwise escalation method and high concentration method in breast cancer cell line BT-474 and lung cancer cell line H2170 with HER2 amplification. E… (full text at CIViC) PMID 31856375 · Takeda et al., 2020 · Open in CIViC	civic
〃	Malignant Lung Neoplasm	Predictive	D	Supports Resistance	3	submitted	EID12096 Neratinib-resistant cell lines were established by stepwise escalation method and high concentration method in breast cancer cell line BT-474 and lung cancer cell line H2170 with HER2 amplification. E… (full text at CIViC) PMID 31856375 · Takeda et al., 2020 · Open in CIViC	civic

YES1 Amplification + YES1 Overexpression1
CH6953755 + DasatinibSubstitutes	Lung Small Cell Carcinoma	Predictive	D	Supports Sensitivity Response	2	submitted	EID12556 In preclinical small cell lung carcinoma (SCLC) models with YES1 amplification or high expression, treatment with the YES1 inhibitor CH6953755 (30 mg/kg, q2d) or dasatinib (45 mg/kg daily) produced ma… (full text at CIViC) PMID 35988891 · Redin et al., 2022 · Open in CIViC	civic